Search results for "Cardiovascular risk"

showing 10 items of 315 documents

Clinical benefits of ezetimibe use: is absence of proof, proof of absence?

2012

Doggrell reviewed the evidence regarding the clinical benefits of ezetimibe in the July issue of Expert Opinion on Pharmacotherapy [1]. The author concludes that since clinical outcome data are sti...

Pharmacologymedicine.medical_specialtybusiness.industryMEDLINEGeneral Medicinecardiovascular risk ezetimibe lipids therapyPharmacotherapyEzetimibeExpert opinionMedicinePharmacology (medical)Outcome databusinessIntensive care medicinemedicine.drug
researchProduct

Natural approaches in metabolic syndrome management

2017

Metabolic syndrome (MetS) is characterized as a group of cardiometabolic risk factors that raise the risk for heart disease and other health problems, such as diabetes mellitus and stroke. Treatment strategies include pharmacologic interventions and supplementary (or "alternative") treatments. Nutraceuticals are derived from food sources (isolated nutrients, dietary supplements and herbal products) that are purported to provide health benefits, in addition to providing basic nutritional value. Nutraceuticals are claimed to prevent chronic diseases, improve health, delay the aging process, increase life expectancy, and support the structure and function of the body. The study of the benefici…

Polyphenolmedicine.medical_specialtyHeart diseaseOmega-3 fatty acid030204 cardiovascular system & hematologyVitamin03 medical and health sciences0302 clinical medicineNutraceuticalmetabolicDiabetes mellitusMacroelementmedicineIn patient030212 general & internal medicineDosingIntensive care medicineStrokepolyphenolsmetabolic syndrome managementnutraceuticalsomega-3 fatty acidsbusiness.industryMedicine (all)General MedicinevitaminsCardiovascular risksyndromemedicine.diseaseMetabolic syndromeBiotechnologymacroelementsLife expectancyNutraceuticalMetabolic syndromebusinessState of the Art PapermanagementArchives of Medical Science
researchProduct

Lifestyle, psychological, socioeconomic and environmental factors and their impact on hypertension during the coronavirus disease 2019 pandemic.

2020

SUMMARY: The coronavirus disease 2019 (COVID-19) pandemic considerably affects health, wellbeing, social, economic and other aspects of daily life. The impact of COVID-19 on blood pressure (BP) control and hypertension remains insufficiently explored. We therefore provide a comprehensive review of the potential changes in lifestyle factors and behaviours as well as environmental changes likely to influence BP control and cardiovascular risk during the pandemic. This includes the impact on physical activity, dietary patterns, alcohol consumption and the resulting consequences, for example increases in body weight. Other risk factors for increases in BP and cardiovascular risk such as smoking…

Psychologic stressCoronavirus disease 2019 (COVID-19)Physiology030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRisk FactorsEnvironmental healthPandemicInternal MedicineHumansMedicine030212 general & internal medicineRisk factorLife StylePandemicsSocioeconomic statuscardiovascular risk coronavirus disease 2019 diet environmental hypertension life style psychological salt severe acute respiratory syndrome coronavirus 2SARS-CoV-2business.industrySmokingCOVID-19Diurnal rhythmsLifestyle factorsBlood pressureSocioeconomic FactorsHypertensionbusinessCardiology and Cardiovascular MedicineStress Psychological
researchProduct

RELATIONSHIP BETWEEN SERUM URIC ACID AND AORTIC STIFFNESS IN UNTREATED HYPERTENSIVE SUBJECTS

2013

Recent studies have reported an association between serum uric acid (SUA) and reduced arterial elasticity. However, in these studies arterial elastic properties have been assessed chiefly by measuring brachial-ankle pulse wave velocity (PWV) or peripheral PWV and only sometimes by using aortic PWV. Moreover, the relationships between SUA and arterial stiffness have never been statistically adjusted for albuminuria. Furthermore, the studies exploring the influence of uric acid on aortic distensibility in subjects with arterial hypertension yielded conflicting results. The aim of our study was to evaluate the relationships between SUA and aortic stiffness in a group of essential hypertensive …

Pulse Wave velocityEssential HypertensionArteriosclerosiUric AcidCardiovascular Risk
researchProduct

Ambulatory Blood Pressure Values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET)

2012

In the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial, telmisartan (T; 80 mg daily) and ramipril (R; 10 mg daily) caused similar clinic blood pressure (BP) reductions, with a similar incidence of cardiovascular and renal events. The R+T combination lowered clinic BP somewhat more with no further cardiovascular or renal protection. The aim of this substudy was to see whether these clinic BP changes reflected the changes of 24-hour BP, a BP with a better prognostic value. In 422 patients in whom 24-hour BP monitoring was performed either before or after 6 to 24 months of treatment, demographic and clinical characteristics were similar in the 3 treated groups.…

RamiprilMalemedicine.medical_specialtyAmbulatory blood pressureDiastoleAngiotensin-Converting Enzyme InhibitorsBlood PressureBenzoateslaw.inventionRandomized controlled trialRamiprillawInternal medicineInternal MedicinemedicineHumansLongitudinal StudiesTelmisartanAntihypertensive AgentsAgedbusiness.industryambulatory blood pressure antihypertensive treatment high cardiovascular risk angiotensin-converting enzyme inhibitors angiotensin receptor blockersMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREBlood Pressure Monitoring AmbulatoryMiddle AgedEndocrinologyBlood pressureTreatment OutcomeTarget drugAmbulatoryHypertensionCardiologyBenzimidazolesDrug Therapy CombinationFemaleTelmisartanbusinessmedicine.drug
researchProduct

Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk

2019

Abstract Aims Studies have shown a non-linear relationship between systolic blood pressure (SBP) and diastolic blood pressure (DBP) and outcomes, with increased risk observed at both low and high blood pressure (BP) levels. We hypothesized that the BP-risk association is different in individuals with and without diabetes at high cardiovascular risk. Methods and results We identified patients with (N = 11 487) or without diabetes (N = 19 450), from 30 937 patients, from 133 centres in 44 countries with a median follow-up of 56 months in the ONTARGET/TRANSCEND studies. Patients had a prior history of stroke, myocardial infarction (MI), peripheral artery disease, or were high-risk diabetics. P…

Ramiprilmedicine.medical_specialtyhypertensionSystoleAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyPeripheral Arterial Disease03 medical and health sciences0302 clinical medicineRamiprilDiastoleRisk FactorsInternal medicineDiabetes mellitusDiabetes MellitusmedicineHumanshigh cardiovascular riskTelmisartan030212 general & internal medicineMyocardial infarctionStrokeRetrospective StudiesHeart Failurediabetesbusiness.industryHazard ratioblood pressureBlood Pressure Determinationmedicine.diseasestrokeHospitalizationmyocardial infarctionBlood pressureCardiovascular DiseasesCase-Control StudiesHeart failureCardiologyDrug Therapy CombinationTelmisartanCardiology and Cardiovascular MedicinebusinessAngiotensin II Type 1 Receptor Blockersmedicine.drugEuropean Heart Journal
researchProduct

Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Resear…

2021

Abstract Background Epidemiological studies in atrial fibrillation (AF) illustrate that clinical complexity increase the risk of major adverse outcomes. We aimed to describe European AF patients’ clinical phenotypes and analyse the differential clinical course. Methods We performed a hierarchical cluster analysis based on Ward’s Method and Squared Euclidean Distance using 22 clinical binary variables, identifying the optimal number of clusters. We investigated differences in clinical management, use of healthcare resources and outcomes in a cohort of European AF patients from a Europe-wide observational registry. Results A total of 9363 were available for this analysis. We identified three …

RegistrieResearch Reportmedicine.medical_specialtyMajor adverse outcomeCardiovascular risk factorsCluster analysisRisk FactorsInternal medicineClinical phenotypeAtrial FibrillationEpidemiologyHumansMedicineRegistriesCluster analysiAtrial fibrillation; Clinical management; Clinical phenotypes; Cluster analysis; Major adverse outcomes; Humans; Phenotype; Registries; Research Report; Risk Factors; Atrial FibrillationClinical managementbusiness.industryProportional hazards modelRisk FactorHazard ratioRAtrial fibrillationClinical phenotypesMajor adverse outcomesGeneral Medicinemedicine.diseaseAtrial fibrillationConfidence intervalPhenotypeCohortMedicineObservational studybusinessResearch ArticleHumanBMC Medicine
researchProduct

Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium

2016

AIMS: Our aims were to evaluate the distribution of troponin I concentrations in population cohorts across Europe, to characterize the association with cardiovascular outcomes, to determine the predictive value beyond the variables used in the ESC SCORE, to test a potentially clinically relevant cut-off value, and to evaluate the improved eligibility for statin therapy based on elevated troponin I concentrations retrospectively.METHODS AND RESULTS: Based on the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) project, we analysed individual level data from 10 prospective population-based studies including 74 738 participants. We investigated the value of adding troponin …

Relative risk reductionPathologymedicine.medical_specialtyBIO/12 - BIOCHIMICA CLINICA E BIOLOGIA MOLECOLARE CLINICAPopulationBiomarker For Cardiovascular Risk Assessment In Europe ; Cardiovascular Risk ; High-sensitivity Assayed Troponin I ; Monica Risk Genetics Archiving And Monograph ; Mortality030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-beingInternal medicineTroponin IMedicineRosuvastatin030212 general & internal medicineMortalityeducationBiomarker for Cardiovascular Risk Assessment in Europe; Cardiovascular risk; High-sensitivity assayed troponin I; MONICA Risk Genetics Archiving and Monograph; Mortalityeducation.field_of_studyFramingham Risk Scorebiologybusiness.industryHazard ratioAbsolute risk reductionBiomarker for Cardiovascular Risk Assessment in EuropeCardiovascular riskMONICA Risk Genetics Archiving and MonographTroponinHigh-sensitivity assayed troponin I3. Good healthCardiologybiology.protein/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingCardiology and Cardiovascular Medicinebusinessmedicine.drugEuropean Heart Journal
researchProduct

Análisis comparativo de las funciones de predicción del riesgo cardiovascular SCORE y Framingham y sus versiones calibradas, SCORE calibrada y REGIDO…

2009

Introducción: Las recomendaciones del ATPIII y las SSCC europeas en prevención primaria cardiovascular aconsejan para la estimación del riesgo individual las funciones de Framingham y SCORE respectivamente. Ambas disponen de versiones calibradas para la población española. Todas, excepto Framingham(ATPIII), han sido derivadas para aplicarlas en un rango de edad limitado. Por otra parte, ninguna de estas funciones predice el riesgo cardiovascular total, ya que SCORE y SCORE calibrada sólo estima el riesgo de muerte y Framingham(ATPIII) y REGICOR el riesgo coronario. Sin embargo todas las medidas preventivas van dirigidas a la prevención de la enfermedad cardiovascular globalmente y las funci…

Riesgo cardiovascular SCORE SCORE calibrada Framingham REGICOR. / Cardiovascular risk SCORE Calibrated SCORE Framingham614Higiene i salut pública. Contaminació. Prevenció d'accidents. Infermeria
researchProduct

Resistin: a new marker of cardiorenal risk?

2010

Riskbusiness.industryBioinformaticsCardiovascular riskDiabetes ComplicationsCardiovascular DiseasesInternal MedicineMedicineAlbuminuriaHumansResistinResistinbusinessUrinary albumin excretionMicroalbuminuria
researchProduct